clinical trial · NCT05388669
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
Janssen Research & Development, LLC·phase3·active not recruiting·n = 418
Advanced or Metastatic Non-small Cell Lung CancerLazertinibAmivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)Amivantamab Intravenous
brief summary
The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantamab, amivantamab subcutaneous and co-formulated with recombinant human hyaluronidase (SC-CF), for subcutaneous administration. This formulation has the potential to enhance both the patient and physician experience with amivantamab by providing easier and accelerated administration.
started
Aug 5, 2022
primary completion
Jan 3, 2024
completion
Jun 30, 2027
last updated
Jun 8, 2026
official title
A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol